Skip to main content
SpringerLink
Log in

The Classification of Calcium Antagonists and their Selection in the Treatment of Hypertension

A Reappraisal

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Summary

Calcium antagonists have become one of the most important advances in the treatment of hypertension since their introduction over 20 years ago. The increase in the number of available calcium antagonists (as new formulations of preexisting drugs or new chemical entities) over recent years has contributed to an ever-changing scenario regarding their appropriate use compared with other anti-hypertensive agents.

As a consequence of this evolving situation, several authors have proposed a 3-generation classification of calcium antagonists currently, or soon to be, marketed in several counties. The classification system is based among other variables, on chemical structure, tissue selectivity, administration frequency and duration of action. In this article, this classification is reviewed and updated on the basis of new information that is available.

In addition, factors which influence the selection of calcium antagonists in the treatment of hypertension in specific patient populations are discussed. As well as pharmacodynamic and pharmacokinetic considerations, these factors also include previous experience with particular drugs in specific patient populations, cost of treatment and drug interactions. Among the dihydropyridine calcium antagonists, the first generation compounds have been clearly superseded and are not recommended for use in hypertensive patients. Whilst the second generation agents represent an adequate treatment, third generation calcium antagonists possess distinct advantages. Definitive confirmation of the role of calcium antagonists in hypertension lies in several ongoing large multicentre trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Furberg CD, Psaty BM, Meyer JV. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation 1995; 92: 1325–31

    Article  Google Scholar 

  2. Alderman MH, Cohen H, Roqué R, et al. Effect of long-acting and short-acting calcium antagonists on cardiovascular outcomes in hypertensive patients. Lancet 1997; 349: 594–8

    Article  PubMed  CAS  Google Scholar 

  3. Ad Hoc Subcommittee of the Liaison Committee of the World Health Organisation and the International Society for Hypertension. Effects of calcium antagonists on the risks of coronary heart disease, cancer and bleeding. J Hypertens 1997; 15: 105–15

    Google Scholar 

  4. Nayler WG. Classification and tissue selectivity of calcium antagonists. Z Kardiol 1990; 79 Suppl. 3: 107–11

    PubMed  CAS  Google Scholar 

  5. Toyo-Oka T, Nayler WG. Third generation calcium entry blockers. Blood Press 1996; 5: 206–8

    Article  PubMed  CAS  Google Scholar 

  6. Mancia G, van Zwieten PA. Third generation calcium antagonists: further developments. Blood Press 1996; 5: 376–7

    Article  PubMed  Google Scholar 

  7. Zanchetti A. Lacidipine — the monograph. Chester: Adis International, 1997: 1–60

  8. Triggle D. Pharmacologic and therapeutic differences among calcium channel antagonists: profile of mibefradil, a new calcium antagonist. Am J Cardiol 1996; 78 Suppl. 9A: 7–12

    Article  PubMed  CAS  Google Scholar 

  9. Lüscher TF, Clozel J-P, Noll G. Pharmacology of the calcium antagonist mibefradil. J Hypertens 1997; 15 Suppl. 3: S11–8

    Google Scholar 

  10. Opie LH. Mechanisms whereby calcium channel antagonists may protect patients with coronary artery disease. Eur Heart J 1997; 18 Suppl. A: A92–104

    Article  PubMed  CAS  Google Scholar 

  11. Messerli FH. Cardioprotection — not all calcium antagonists are created equal: second round. Am J Cardiol 1997; 79: 788–9

    Article  PubMed  CAS  Google Scholar 

  12. Leenen HH. Clinical relevance of 24h blood pressure control by dihydropyridines. Am J Hypertens 1996; 9: 975–1045

    Google Scholar 

  13. Purcell H, Walker DG, Fox K. Calcium antagonists in cardiovascular disease. Br J Clin Pract 1989; 43: 369–79

    PubMed  CAS  Google Scholar 

  14. Ruzicka M, Leenen FHH. Relevance of intermittent increases in sympathetic activity for adverse event outcome on short-acting calcium antagonists. In: Laragh JH, Brenner BM, editors. Hypertension: pathophysiology, diagnosis and management. New York: Raven Press, 1995: 2815–25

    Google Scholar 

  15. Wenzel RR, Allegranza G, Binggeli C, et al. Differential activation of cardiac and peripheral sympathetic nervous system by nifedipine: role of pharmacokinetics. J Am Coll Cardiol 1997; 29: 1607–14

    Article  PubMed  CAS  Google Scholar 

  16. Haria M, Wagstaff AJ. Amlodipine: a reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease. Drugs 1995 Sep; 50(3): 560–86

    Article  PubMed  CAS  Google Scholar 

  17. van Zwieten P, Pfaffendorf M. Pharmacology of the dihydropyridine calcium antagonists: relationship between lipophilicity and pharmacodynamic responses. J Hypertens 1993; 11 Suppl. 6: S3–8

    Article  Google Scholar 

  18. Meredith PA, Perloff D, Mancia G, et al.. Blood pressure variability and its implications for antihypertensive therapy. Blood Press 1995; 4: 5–11

    Article  PubMed  CAS  Google Scholar 

  19. Furberg CD, Pahor M, Psaty BM. The unnecessary controversy. Eur Heart J 1996; 17: 1142–7

    Article  PubMed  CAS  Google Scholar 

  20. Littler WA, Sheridan DJ, UK Study Group. Placebo controlled trial of felodipine in patients with mild to moderate heart failure. Br Heart J 1995; 73: 428–33

    Article  PubMed  CAS  Google Scholar 

  21. Dougall HT, McLay J. A comparative review of the adverse effects of calcium antagonists. Drug Saf 1996 Aug; 15(2): 91–106

    Article  PubMed  CAS  Google Scholar 

  22. Packer M, O’Connor CM, Ghali JK, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 1996; 335: 1107–14

    Article  PubMed  CAS  Google Scholar 

  23. Lindholm LH, Tcherdakoff P, Zanchetti A. Safety aspects with lacidipine: a slow onset, long-acting calcium antagonist. Blood Press 1996; 5: 241–9

    Article  PubMed  CAS  Google Scholar 

  24. De Vries RJM, Dunselman PHJM, Chin Kon Sung UG, et al. Effects of lacidipine on peak oxygen consumption, neurohormones and invasive haemodynamics in patients with mild to moderate chronic heart failure. Heart 1996; 75: 159–64

    Article  PubMed  Google Scholar 

  25. Cohn JN, Ziesche S, Smith R, et al. Effect of the calcium antagonist felodopine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Study Trial (V-HeFT) Study Group. Circulation 1997; 96: 856–63

    CAS  Google Scholar 

  26. Ursini F. Tissue protection by lacidipine: insights from redox behaviour. J Cardiovasc Pharmacol 1997; 30 Suppl. 2: 28–30

    Google Scholar 

  27. Lüscher TF. From the treatment of hypertension to complete vessel protection: concepts, experimental data, and clinical perspectives. J Cardiovasc Pharmacol 1997; 30 Suppl. 2: 20–7

    Google Scholar 

  28. Lüscher TF, Vanhoutte PM. The endothelium modulator of cardiovascular function. Boca Raton (FL): CRC Press, 1990: 1–25

    Google Scholar 

  29. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362: 801–9

    Article  PubMed  CAS  Google Scholar 

  30. Vanhoutte PM. Vascular endothelium and Ca2+-antagonists. J Cardiovasc Pharmacol 1988; 14 Suppl. 11: 76–80

    Google Scholar 

  31. Goerre S, Wenk M, Bartsch P, et al. Endothelin-1 in pulmonary hypertension associated with high-altitude exposure. Circulation 1995; 91: 359–64

    Article  PubMed  CAS  Google Scholar 

  32. Kiowski W, Lüscher TF, Linder L, et al. Endothelin-1—induced vasoconstriction in humans: reversal by calcium channel blockade but not by nitrovasodilators or endothelium-derived relaxing factor. Circulation 1991; 83: 469–75

    Article  PubMed  CAS  Google Scholar 

  33. Kung CF, Moreau P, Takase H, et al. L-NAME hypertension alters endothelial and smooth muscle function in rat aorta. Prevention by trandolapril and verapamil. Hypertension 1995; 26: 744–51

    CAS  Google Scholar 

  34. Moreau P, Takase H, Kung CF, et al. Structure and function of the rat basilar artery during chronic nitric oxide synthase inhibition. Stroke 1995; 26: 1922–9

    Article  PubMed  CAS  Google Scholar 

  35. Takase H, Moreau P, Kung CF, et al. Antihypertensive therapy prevents endothelial dysfunction in chronic nitric oxide deficiency. Effect of verapamil and trandolapril. Hypertension 1996; 27: 25–31

    CAS  Google Scholar 

  36. Noll G, Buhler FR, Lüscher TF. Different potency of endothelium-derived relaxing factors against thromboxane, endothelin and potassium chloride in porcine intramyocardial resistance arteries. J Cardiovasc Pharmacol 1991; 18: 120–6

    Article  PubMed  CAS  Google Scholar 

  37. Goto K, Kasuya Y, Matsuki N, et al. Endothelin activates the dihydropyridine-sensitive, voltage-dependent Ca2+channel in vascular smooth muscle. Proc Natl Acad Sci USA 1989; 86: 3915–8

    Article  PubMed  CAS  Google Scholar 

  38. Yang Z, Bauer E, von Segesser L, et al. Different mobilization of calcium in endothelin-1—induced contractions in human arteries and veins: effects of calcium antagonists. J Cardiovasc Pharmacol 1990; 16: 654–60

    Article  PubMed  CAS  Google Scholar 

  39. Lüscher TF. The endothelium in hypertension: bystander, target or mediator? J Hypertens 1994; 12 Suppl. 10: S105–16

    Google Scholar 

  40. Creager MA, Roddy MA. Effect of captopril and enalapril on endothelial function in hypertensive patients. Hypertension 1994; 24: 499–505

    Article  PubMed  CAS  Google Scholar 

  41. Panza JA, Quyyumi AA, Callahan TS, et al. Effect of antihypertensive treatment on endothelium-dependent vascular relaxation in patients with essential hypertension. J Am Coll Cardiol 1993; 21: 1145–51

    Article  PubMed  CAS  Google Scholar 

  42. Frielingsdorf J, Seiler C, Kaufmann P, et al. Normalization of abnormal coronary vasomotion by calcium antagonists in patients with essential hypertension. Circulation 1996; 93: 1380–7

    Article  PubMed  CAS  Google Scholar 

  43. Zanchetti A, Chalmers J, Arakawa K, et al. 1993 Guidelines for the management of mild hypertension: memorandum from a World Health Organisation/International Society of Hypertension meeting. J Hypertens 1993; 11: 905–18

    Article  Google Scholar 

  44. Ferrari R. Major differences among the three classes of calcium antagonists. Eur Heart J 1997; 18 Suppl. A: A56–70

    Article  PubMed  CAS  Google Scholar 

  45. DAVIT-II study — Danish Study Group on Verapamil in Myocardial Infarction. Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial II — DAVIT II). Am J Cardiol 1990; 66: 779–85

    Article  Google Scholar 

  46. Cziraky MJ, Mehra IV, Wilson MD, et al. Current issues in treating the hypertensive patient with diabetes: focus on diabetic nephropathy. Ann Pharmacother 1996; 30: 791–801

    PubMed  CAS  Google Scholar 

  47. Bakris GL. Combination therapy for hypertension and renal disease in diabetics as compared to non-diabetics. In: Mogensen CE, editor. The kidney and hypertension in diabetes mellitus. 3rd ed. Boston: Kluwer Academic, 1997: 561–8

    Google Scholar 

  48. Dahlöff B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients: a meta-analysis of 109 treatment studies. Am J Hypertens 1992; 5: 95–110

    Google Scholar 

  49. Hansen JF, Hagerup L, Sigurd B, et al. Cardiac event rates after acute myocardial infarction in patients treated with verapamil and trandolapril versus trandolapril alone. Am J Cardiol 1997; 79: 738–41

    Article  PubMed  CAS  Google Scholar 

  50. Nayler WG. Amlodipine. Berlin, Heidelberg: Springer-Verlag, 1993

    Book  Google Scholar 

  51. Urquhart J. Ascertaining how much compliance is enough with out-patient antibiotic regimens. Postgrad Med J 1992; 68 Suppl. 3: 49–59

    Google Scholar 

  52. McMurray J, Murdoch D. Calcium-antagonist controversy: the long and short of it? Lancet 1997; 349: 585–6

    Article  PubMed  CAS  Google Scholar 

  53. Psaty BM, Smith NL, Siscovick DS, et al. Health outcomes associated with antihypertensive therapies used as first-line agents: a systematic review and meta-analysis. JAMA 1997; 277: 739–45

    Article  PubMed  CAS  Google Scholar 

  54. Staessen JA, and others for the Systolic Hypertension in Europe (Syst-Eur) Trial investigators. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997; 350: 757–63

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Cardiology, University Hospital Zurich, Rämistrasse 100, CH-8091, Zurich, Switzerland

    Thomas F. Lüscher & Francesco Cosentino

  2. IRCCS, Neuromed, Pozzilli (IS), Italy

    Francesco Cosentino

Authors
  1. Thomas F. Lüscher
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Francesco Cosentino
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lüscher, T.F., Cosentino, F. The Classification of Calcium Antagonists and their Selection in the Treatment of Hypertension. Drugs 55, 509–517 (1998). https://doi.org/10.2165/00003495-199855040-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199855040-00003

Keywords

Search

Navigation